NDAORALTABLETPriority Review
Approved
Nov 1959
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Data completeness
3/8 — Basic
Priority Review
ISORDIL (isosorbide dinitrate) by Bausch + Lomb. Approved for nitrate vasodilator [epc]. First approved in 1959.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISORDIL is an oral nitrate vasodilator approved in 1959 for angina pectoris and related cardiac conditions. It works by relaxing vascular smooth muscle and reducing cardiac preload, improving coronary blood flow and oxygen delivery to the heart. The drug is indicated for acute relief and prophylaxis of angina attacks.
LOE Approaching
As LOE approaches, teams will shift focus to generic optimization, cost containment, and leveraging brand loyalty to delay erosion in a competitive generic market.
Mechanism of Action
Pharmacologic Class:
Nitrate Vasodilator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ISORDIL offers limited career growth opportunity given its LOE approaching status and mature, generic-saturated market. Roles are primarily defensive and cost-focused, suited for professionals seeking stable, lower-intensity portfolio management rather than high-growth launch environments.
Brand ManagerField Sales Representative
Worked on ISORDIL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.